BOTHELL, Wash.--(BUSINESS WIRE)--Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that it has initiated a phase IIb clinical trial of SGN-33 (lintuzumab), a monoclonal antibody, in combination with a low-dose regimen of the chemotherapeutic agent cytarabine for patients with acute myeloid leukemia (AML). The randomized, double-blind, placebo-controlled study is designed to assess whether this combination regimen extends survival compared to cytarabine alone in previously untreated patients 60 years of age and older. The study will accrue more than 200 patients at multiple cancer centers around the world.
